Articles

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach

Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Molecular Medicine, University of Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Molecular Medicine, University of Pavia, Italy;Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Molecular Medicine, University of Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Molecular Medicine, University of Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Molecular Medicine, University of Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Molecular Medicine, University of Pavia, Italy
Nutrition and Dietetics Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Molecular Medicine, University of Pavia, Italy;Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Molecular Medicine, University of Pavia, Italy
Vol. 99 No. 4 (2014): April, 2014 https://doi.org/10.3324/haematol.2013.095463